By Pete Gallo One of the most spectacular payoffs in public stocks so far this year has been Chilton Investment Co.’s incorrigible portfolio bet on a smaller-cap pharmaceutical specialist called Vivus, whose share-price trajectory has surged from burgeoning to ballistic, thanks to recent regulatory approvals for its experimental weight-loss drug,